Your session is about to expire
← Back to Search
Nicotinic Acetylcholine Receptor Partial Agonist
OC-01 (varenicline 0.6mg/ml) Nasal Spray for Dry Eye Syndrome
Phase 4
Waitlist Available
Research Sponsored by Center for Ophthalmic and Vision Research, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights
Drug Has Already Been Approved
Pivotal Trial
Summary
This trial will compare the effectiveness of a new nasal spray medication to a placebo in reducing the symptoms of dry eye disease in people who wear soft contact lenses.
Eligible Conditions
- Dry Eye Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
CLDEQ-8 scores at 4 weeks
Contact lens wear time at 4 weeks
Secondary study objectives
Automated tear breakup time
CLDEQ-8 scores at 8 weeks
Contact lens wear time at 8 weeks
+2 moreAwards & Highlights
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: OC-01 (varenicline 0.6mg/ml) nasal sprayExperimental Treatment1 Intervention
Intranasal delivery of OC-01 nasal spray twice daily (BID)
Group II: Placebo (vehicle) nasal sprayPlacebo Group1 Intervention
Intranasal delivery of placebo vehicle nasal spray twice daily (BID)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
OC-01 (varenicline 0.6mg/ml) Nasal Spray
2021
Completed Phase 4
~80
Find a Location
Who is running the clinical trial?
Center for Ophthalmic and Vision Research, LLCLead Sponsor
1 Previous Clinical Trials
50 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger